Immediate Evaluation and Management of Heavy Menstrual Bleeding on Enhertu
You should immediately assess her hemodynamic status, check a complete blood count with iron studies, and initiate tranexamic acid while coordinating urgent multidisciplinary care with gynecology and hematology. Heavy menstrual bleeding is a known but under-recognized complication of cancer treatment that requires prompt intervention to prevent anemia, transfusion requirements, and quality of life deterioration 1.
Initial Assessment
First, determine the severity of bleeding:
- Check orthostatic vital signs to assess hemodynamic stability 2
- Obtain CBC with differential to evaluate for anemia and thrombocytopenia (Enhertu commonly causes neutropenia and can affect platelet counts) 3
- Check serum ferritin to assess iron stores 2
- Quantify bleeding using a pictorial blood assessment chart (PBAC) if possible - scores >100 indicate heavy menstrual bleeding 4, 5
The FDA label for Enhertu does not specifically list heavy menstrual bleeding as a common adverse event, but the drug causes significant hematologic toxicity including neutropenia (65% of patients) and thrombocytopenia (48% of patients) at the 5.4 mg/kg dose 3. This can compound menstrual bleeding severity.
Immediate Medical Management
For Acute Heavy Bleeding:
Start tranexamic acid immediately - this is the first-line antifibrinolytic agent with proven efficacy in reducing menstrual blood loss 6, 2, 7. Dosing:
- Oral: 1300 mg three times daily during menses
- IV: 10 mg/kg every 6-8 hours if unable to take oral or hemodynamically unstable 6
High-dose hormonal therapy if hemodynamically stable and no contraindications:
- Combined oral contraceptives: 1 pill every 8 hours for 7 days, then taper 8, 2
- Oral progestins: Medroxyprogesterone acetate 20 mg three times daily for 7 days 8, 2
Critical Consideration - Thrombotic Risk:
The decision to use estrogen-containing contraceptives requires careful risk-benefit analysis 8. Cancer patients, particularly those on chemotherapy like Enhertu, have elevated VTE risk. However, the 2021 ACOG guidelines state that estrogen use should be "tailored to the individual patient after collaborative consideration" with close monitoring 8. Given her young age (27) and presumably no prior VTE history, combined hormonal contraceptives may be considered for acute control, but progestin-only options are safer 8, 9.
Multidisciplinary Coordination
Urgent gynecology consultation is essential 1. The 2025 interdisciplinary guidelines emphasize that gynecologists should "take the lead and central role in discussing and offering medical and procedural therapies" for acute bleeding 1.
Involve her oncologist immediately to:
- Review current platelet and neutrophil counts before any intervention
- Discuss whether Enhertu dose modification or delay is needed 3
- Coordinate timing of any procedures with her chemotherapy schedule
- Ensure she's not approaching expected nadir (lowest blood count point) 9
Supportive Care
If she's anemic (hemoglobin <10 g/dL or symptomatic):
- IV iron infusion for faster repletion than oral iron 1
- Blood transfusion if hemoglobin <7 g/dL or symptomatic with hemoglobin 7-10 g/dL 1
Bridging to Long-Term Management
Once acute bleeding is controlled, do not assume the problem is resolved 10. The 2026 phase-based management framework emphasizes a vulnerable "bridging stabilization" period after initial control 10:
Bridging options (until definitive therapy):
- Continuous progestin-only pills (norethindrone 5 mg daily) 10, 7
- Depot medroxyprogesterone acetate (150 mg IM every 12 weeks) 10
- Tranexamic acid during each menstrual period 10, 7
Definitive Long-Term Management
Levonorgestrel-releasing IUD (52 mg) is the most effective long-term option for heavy menstrual bleeding 2, 7. However, insertion should be delayed until:
- Bleeding is controlled
- Platelet count >50,000/μL (ideally >80,000/μL)
- Neutrophil count adequate to reduce infection risk
- Not within 7-10 days of chemotherapy nadir 9, 10
The IUD should be viewed as "definitive long-term maintenance" rather than acute or bridging therapy 10.
Common Pitfalls to Avoid
Do not dismiss this as "just a side effect" - HMB in cancer patients leads to iron deficiency anemia, transfusion requirements, and severely impaired quality of life 1, 5
Do not assume all hormonal contraceptives increase thrombosis risk equally - progestin-only methods (pills, implants, IUDs) do NOT increase VTE risk, but many patients incorrectly believe they do 5
Do not insert an IUD during active heavy bleeding or when counts are low - this increases infection and bleeding complications 9, 10
Do not manage this alone - the 2025 guidelines strongly emphasize that "multidisciplinary care" with gynecology and hematology/oncology is essential for optimal outcomes 1
Do not forget contraception counseling - Enhertu causes fetal harm and requires effective contraception for 7 months after the last dose 3
Monitoring Plan
- Weekly CBC until bleeding controlled and counts stable
- Reassess bleeding severity at each menstrual cycle using PBAC scoring
- Ferritin every 4-6 weeks until repleted
- Gynecology follow-up within 1-2 weeks after acute episode for definitive management planning 1
The key message: This requires urgent action, not reassurance. Heavy menstrual bleeding in cancer patients is undertreated 5, and early aggressive management prevents serious complications while maintaining quality of life during cancer treatment.